Rxo (RXO) Price to Sales (2022 - 2026)

Rxo (RXO) has reported Price to Sales for 5 consecutive years, with 2.56 the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Price to Sales rose 41.2% year-over-year to 2.56; the trailing twelve-month figure through Jun 2026 stood at 0.75 (up 61.16% YoY), and the FY2025 full-year result was 0.36, down 48.3% from the prior year.
• Price to Sales climbed to 2.56 in Q2 2026 per RXO's latest filing, from 1.69 in the prior quarter.
• Across five years, Price to Sales topped out at 4.33 in Q3 2024 and bottomed at 1.41 in Q4 2025.
• Historically, Price to Sales has averaged 2.38 across 5 years, with a median of 2.27 in 2023.
• The sharpest annual moves came in 2024 and 2025: Price to Sales soared 83.03% in 2024, then sank 58.97% in 2025.
• Over 5 years, Price to Sales stood at 1.79 in 2022, then soared by 55.7% to 2.78 in 2023, then slumped by 31.45% to 1.91 in 2024, then retreated by 25.97% to 1.41 in 2025, then jumped by 81.58% to 2.56 in 2026.
• According to Business Quant data, Price to Sales over the past three periods registered 2.56, 1.69, and 1.41 for Q2 2026, Q1 2026, and Q4 2025 respectively.